Swiss National Bank Invests $1.50 Million in CytomX Therapeutics, Inc. $CTMX

Swiss National Bank acquired a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the first quarter, Holdings Channel reports. The firm acquired 319,600 shares of the biotechnology company’s stock, valued at approximately $1,502,000.

Several other large investors also recently added to or reduced their stakes in the business. Orbimed Advisors LLC purchased a new position in CytomX Therapeutics during the second quarter worth about $19,208,000. Commodore Capital LP bought a new position in CytomX Therapeutics in the 2nd quarter worth about $17,462,000. Perceptive Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $15,876,000. State Street Corp raised its holdings in shares of CytomX Therapeutics by 697.1% in the 4th quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock valued at $21,900,000 after acquiring an additional 4,495,949 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at about $6,505,000. Institutional investors own 67.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CTMX. Wall Street Zen raised CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Zacks Research raised shares of CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. HC Wainwright dropped their target price on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Wolfe Research assumed coverage on shares of CytomX Therapeutics in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CytomX Therapeutics has a consensus rating of “Buy” and a consensus target price of $12.10.

CytomX Therapeutics Stock Down 5.5%

Shares of CTMX stock opened at $3.10 on Friday. The business has a 50-day moving average price of $3.39 and a two-hundred day moving average price of $4.31. CytomX Therapeutics, Inc. has a 12-month low of $1.72 and a 12-month high of $8.21. The firm has a market cap of $527.59 million, a P/E ratio of -7.56 and a beta of 2.08.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The firm had revenue of $10.26 million during the quarter, compared to analysts’ expectations of $4.68 million. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%. As a group, research analysts expect that CytomX Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.